Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Everest Approved for China Phase II trial of Trodelvy® in TROP-2 Cancers

publication date: Mar 31, 2021

Shanghai's Everest Medicines said it is approved to conduct a China Phase II trial of Trodelvy® in patients with cancers that have high TROP-2 expression. Everest plans to enroll 180 patients with esophageal squamous cell carcinoma, gastric cancer and cervical cancer. In 2019, Everest acquired Greater China rights to Trodelvy in an agreement worth up to $835 million from Immunomedics, which was bought by Gilead. Last year, Everest began a registrational China Phase IIb trial of the candidate to treat metastatic triple-negative breast cancer. More details....

Stock Symbols: (HK: 1952) (NSDQ: GILD)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here